Business Context and Reporting Period
Company: Infosys Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: January 16, 2025
Reporting Period: Quarter and nine months ended December 31, 2024
This filing serves as a cover document furnishing the SEC with public disclosures regarding Infosys's results of operations and financial condition. The actual financial data is contained in attached exhibits (Exhibit 99.2 for IFRS USD results and Exhibit 99.3 for Ind-AS results) rather than within the text of this Form 6-K.
Key Financial Metrics
The text of this filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press releases (Exhibits 99.2 and 99.3).
Material Changes and Corporate Actions
- Share Capital Increase: Effective January 16, 2025, the issued and subscribed share capital increased to INR 20,76,13,73,730, divided into 4,15,22,74,746 equity shares of INR 5 each.
- Stock Exercises: The Board approved the allotment of 5,552 equity shares pursuant to the exercise of Restricted Stock Units (RSUs) by eligible employees:
- 1,982 shares under the 2015 Incentive Compensation Plan.
- 3,570 shares under the Infosys Expanded Stock Ownership Program 2019.
- Executive Compensation: The Board approved annual time-based stock incentives (RSUs) for CEO & MD Salil Parekh with a market value of INR 3 crore as of the grant date. These will be granted effective February 1, 2025, under the 2015 Stock Incentive Compensation Plan.
- Governance Update: The Board approved amendments to the Whistleblower policy.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook statements, management commentary on future performance, or a discussion of risks and contingencies. These items are expected to be detailed in the attached press releases (Exhibits 99.2 and 99.3).
Investor Verification Checklist
- Review Exhibit 99.2 for detailed IFRS financial results (revenue, profit, margins) for the quarter and nine months ended December 31, 2024.
- Review Exhibit 99.3 for financial results under Indian Accounting Standards (Ind-AS).
- Verify the impact of the new share allotment (5,552 shares) on total outstanding share count and diluted earnings per share.
- Confirm the valuation methodology for the CEO's RSU grant (market price at close of trading immediately preceding the grant date).
- Access the updated Whistleblower policy via the company's investor relations website.